Znn3bq.jpeg
ÉÇÍ·´óѧº£Ñó¿ÆÑ§½ÓÊܵ÷¼Á
²é¿´: 1286  |  »Ø¸´: 5
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

polarmouse

Ìú³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÁ½¶Î·­Ò룬·Ç³£½ô¼±£¬¸Ð¼¤ÌéÁã

In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A. Blood samples were taken over 72 h of each treatmentperiod. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
   Co-administration of A withB, C or D had no effect on A maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC). Similarly, A did not affect the Cmax or AUC for the co-administered drug, except for slight extensions of the 90% CI for the ratio of geometric means for B AUC (upper limit 1.29) andC Cmax (lower limit 0.75). All monotherapies and combination therapies were well tolerated.
    A can be co-administered with B¡¢C¡¢Dwithout dose adjustment of either drug

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Blood samples were taken over 72 h of each treatment period. Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination:monotherapy being within the range of 0.80¨C1.25 ¡£
ÿ¸ö´¦ÀíÖÜÆÚ72Сʱ֮ºó½«ÑªÒºÑù±¾È¡³ö¡£¸ù¾Ý¼¸ºÎ·½·¨ºÍ»ìºÏÎï90%ÖÃÐÅÇø¼ä£¨ÔÚ0.8-1.25·¶Î§Äڵĵ¥Ò»ÖÎÁÆ£©µÄ±ÈÖµÀ´Åж¨½»²æ·´Ó¦ÖÐÊÇ·ñȱ·¦PK¡£
6Â¥2011-05-08 16:09:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 6 ¸ö»Ø´ð

Mally89

Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)

T_T

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
sltmac(½ð±Ò+41, ·­ÒëEPI+1): 2011-05-16 07:52:15
sltmac: ¼ÌÐøÅ¬Á¦~~ 2011-05-16 07:52:30
In open-label, randomized, three-period, three-treatment crossover studies, 10 subjects received 10 mg A, 45 mg B or the combination, while20 subjects received 20 mg A, 1000 mg C or the combination. In an open-label, randomized, five-period, five-treatment, unbalanced crossover study, 12 subjects first received 20 mg A, 4 mg D or the combination, and afterward 100 mg sitagliptin or sitagliptin plus 20 mg A¡£
ÔÚ½øÐгÖÐøÈý¸öÖÜÆÚ£¬Ëæ»ú¿ª·Å±ê¼ÇµÄÈý¸ö´¦Àí½»²æÖÎÁÆÑо¿µ±ÖУ¬10¸öÑù±¾ÖмÓÈë10mgµÄA£¬45mgµÄB»òÕß¶þÕߵĻìºÏÎÁíÍâ20¸öÑù±¾ÖмÓÈë20mgµÄA¡¢1000mgµÄC»òÕß¶þÕߵĻìºÏÎï¡£ÔÚÁíÒ»¸öËæ»ú¿ª·Å±ê¼Ç£¬Î¬³Ö5¸öÖÜÆÚµÄ5¸ö½»²æ²»Æ½ºâ´¦ÀíÑо¿µ±ÖУ¬Ê×ÏÈÏò12¸öÑù±¾ÖмÓÈë20mg A£¬4mg D»òÕß¶þÕß»ìºÏÎȻºóÔÙ¼ÓÈë100mgÎ÷ËûÁÐÍ¡»ò¼ÓÓÐ20mgAµÄÎ÷ËûÁÐÍ¡¡£
5Â¥2011-05-08 15:22:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 291 Çóµ÷¼Á +37 »¯¹¤2026½ì±ÏÒµÉ 2026-04-09 38/1900 2026-04-15 00:27 by lihaoda1994
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏôóÉúÎïѧ332Çóµ÷¼Á +11 ³Ø³Ø³Ø³Ø³Ø³Ø 2026-04-08 11/550 2026-04-13 14:10 by ¿ÆÑÐÂÛ
[¿¼ÑÐ] 0831Ò»ÂÖµ÷¼Áʧ°ÜÇóÖú +10 СÐÜî£î£_s 2026-04-11 10/500 2026-04-12 22:43 by ³¤¹­°Á
[¿¼ÑÐ] 0860004 Çóµ÷¼Á 309·Ö +9 Yin DY 2026-04-08 9/450 2026-04-11 22:55 by dongdian1
[¿¼ÑÐ] Ò»Ö¾Ô¸Ïôó0856£¬306Çóµ÷¼Á +15 Bblinging 2026-04-11 15/750 2026-04-11 22:53 by 314126402
[¿¼ÑÐ] Çóµ÷¼Á +3 θ¾·ÂÎÀÛÁË 2026-04-11 5/250 2026-04-11 14:13 by luhong1990
[¿¼ÑÐ] 085410-273Çóµ÷¼Á +6 X1999 2026-04-10 6/300 2026-04-11 10:32 by Delta2012
[¿¼ÑÐ] 293Çóµ÷¼Á +6 ÓÂÔ¶¿â°®314 2026-04-08 6/300 2026-04-11 10:08 by zhq0425
[¿¼ÑÐ] 309Çóµ÷¼Á +14 wdhw 2026-04-10 15/750 2026-04-10 21:06 by zhouxiaoyu
[¿¼ÑÐ] 314Çóµ÷¼Á +18 xhhdjdjsjks 2026-04-09 19/950 2026-04-10 18:53 by HPUCZ
[¿¼ÑÐ] ±¾9 Ò»Ö¾Ô¸Î÷¹¤´ó085601 324Çóµ÷¼Á +5 wysyjs25 2026-04-10 5/250 2026-04-10 16:57 by luoyongfeng
[¿¼ÑÐ] »úеר368 ÓÐÈ¥´¦Âð +4 ÖÖ´óÊ÷ 2026-04-10 4/200 2026-04-10 15:31 by jiajinhpu
[¿¼ÑÐ] Çൺ¿Æ¼¼´óѧ²ÄÁÏѧԺ£¬»·¾³Ñ§Ôºµ÷¼Á²¹Â¼4ÔÂ10ÈÕÒÔǰ¶¼¿ÉÒÔ +3 1Çà¿Æ´ó¡£ 2026-04-09 5/250 2026-04-10 09:58 by ôæôæÒ»ÊéÉú
[¿¼ÑÐ] Òѵ÷¼Á +18 ²ñ¿¤Ã¨_ 2026-04-09 19/950 2026-04-09 22:10 by ²ñ¿¤Ã¨_
[¿¼ÑÐ] 070300»¯Ñ§ Çóµ÷¼Á +13 73372112 2026-04-08 13/650 2026-04-09 20:22 by maddjdld
[¿¼ÑÐ] µ÷¼Á +19 2261744733 2026-04-08 19/950 2026-04-09 19:11 by vgtyfty
[¿¼ÑÐ] ²ÄÁÏר˶³õÊÔ·Ö332Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ£¬ +12 ¹ÊÈË?? 2026-04-09 12/600 2026-04-09 18:34 by Ccclqqq
[¿¼ÑÐ] 334Çóµ÷¼Á +16 Riot2025 2026-04-08 17/850 2026-04-09 09:28 by wdyheheeh
[¿¼ÑÐ] ÉúÎïѧ328·ÖÇóµ÷¼Á +9 ÉÁµçkkl 2026-04-08 10/500 2026-04-08 21:42 by liuhuiying09
[¿¼ÑÐ] Çóµ÷¼Á£¬ÏÖÔÚ»¹ÄÜÌîµÄ +3 Éϰ¶Ð¡Ó¨¼ÓÓÍ 2026-04-08 3/150 2026-04-08 14:30 by zhq0425
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û